King's College London

Research portal

Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine

Research output: Contribution to journalArticle

Standard

Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. / Lee, Charlotte A.; Sinha, Siddharth; Fitzpatrick, Emer; Dhawan, Anil.

In: Journal of molecular medicine (Berlin, Germany), Vol. 96, No. 6, 06.2018, p. 469-481.

Research output: Contribution to journalArticle

Harvard

Lee, CA, Sinha, S, Fitzpatrick, E & Dhawan, A 2018, 'Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine', Journal of molecular medicine (Berlin, Germany), vol. 96, no. 6, pp. 469-481. https://doi.org/10.1007/s00109-018-1638-5

APA

Lee, C. A., Sinha, S., Fitzpatrick, E., & Dhawan, A. (2018). Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. Journal of molecular medicine (Berlin, Germany), 96(6), 469-481. https://doi.org/10.1007/s00109-018-1638-5

Vancouver

Lee CA, Sinha S, Fitzpatrick E, Dhawan A. Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. Journal of molecular medicine (Berlin, Germany). 2018 Jun;96(6):469-481. https://doi.org/10.1007/s00109-018-1638-5

Author

Lee, Charlotte A. ; Sinha, Siddharth ; Fitzpatrick, Emer ; Dhawan, Anil. / Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. In: Journal of molecular medicine (Berlin, Germany). 2018 ; Vol. 96, No. 6. pp. 469-481.

Bibtex Download

@article{f0002fd5a3ba40e7ae83db878f005b85,
title = "Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine",
abstract = "Human hepatocyte transplantation has been actively perused as an alternative to liver replacement for acute liver failure and liver-based metabolic defects. Current challenges in this field include a limited cell source, reduced cell viability following cryopreservation and poor engraftment of cells into the recipient liver with consequent limited life span. As a result, alternative stem cell sources such as pluripotent stem cells, fibroblasts, hepatic progenitor cells, amniotic epithelial cells and mesenchymal stem/stromal cells (MSCs) can be used to generate induced hepatocyte like cells (HLC) with each technique exhibiting advantages and disadvantages. HLCs may have comparable function to primary human hepatocytes and could offer patient-specific treatment. However, long-term functionality of transplanted HLCs and the potential oncogenic risks of using stem cells have yet to be established. The immunomodulatory effects of MSCs are promising, and multiple clinical trials are investigating their effect in cirrhosis and acute liver failure. Here, we review the current status of hepatocyte transplantation, alternative cell sources to primary human hepatocytes and their potential in liver regeneration. We also describe recent clinical trials using hepatocytes derived from stem cells and their role in improving the phenotype of several liver diseases.",
keywords = "Fibroblast, Hepatic progenitor cells, Hepatocyte transplantation, Induced pluripotent stem cells, Liver regeneration, Mesenchymal stem/stromal cell",
author = "Lee, {Charlotte A.} and Siddharth Sinha and Emer Fitzpatrick and Anil Dhawan",
year = "2018",
month = jun,
doi = "10.1007/s00109-018-1638-5",
language = "English",
volume = "96",
pages = "469--481",
journal = "Journal of molecular medicine (Berlin, Germany)",
issn = "0946-2716",
number = "6",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine

AU - Lee, Charlotte A.

AU - Sinha, Siddharth

AU - Fitzpatrick, Emer

AU - Dhawan, Anil

PY - 2018/6

Y1 - 2018/6

N2 - Human hepatocyte transplantation has been actively perused as an alternative to liver replacement for acute liver failure and liver-based metabolic defects. Current challenges in this field include a limited cell source, reduced cell viability following cryopreservation and poor engraftment of cells into the recipient liver with consequent limited life span. As a result, alternative stem cell sources such as pluripotent stem cells, fibroblasts, hepatic progenitor cells, amniotic epithelial cells and mesenchymal stem/stromal cells (MSCs) can be used to generate induced hepatocyte like cells (HLC) with each technique exhibiting advantages and disadvantages. HLCs may have comparable function to primary human hepatocytes and could offer patient-specific treatment. However, long-term functionality of transplanted HLCs and the potential oncogenic risks of using stem cells have yet to be established. The immunomodulatory effects of MSCs are promising, and multiple clinical trials are investigating their effect in cirrhosis and acute liver failure. Here, we review the current status of hepatocyte transplantation, alternative cell sources to primary human hepatocytes and their potential in liver regeneration. We also describe recent clinical trials using hepatocytes derived from stem cells and their role in improving the phenotype of several liver diseases.

AB - Human hepatocyte transplantation has been actively perused as an alternative to liver replacement for acute liver failure and liver-based metabolic defects. Current challenges in this field include a limited cell source, reduced cell viability following cryopreservation and poor engraftment of cells into the recipient liver with consequent limited life span. As a result, alternative stem cell sources such as pluripotent stem cells, fibroblasts, hepatic progenitor cells, amniotic epithelial cells and mesenchymal stem/stromal cells (MSCs) can be used to generate induced hepatocyte like cells (HLC) with each technique exhibiting advantages and disadvantages. HLCs may have comparable function to primary human hepatocytes and could offer patient-specific treatment. However, long-term functionality of transplanted HLCs and the potential oncogenic risks of using stem cells have yet to be established. The immunomodulatory effects of MSCs are promising, and multiple clinical trials are investigating their effect in cirrhosis and acute liver failure. Here, we review the current status of hepatocyte transplantation, alternative cell sources to primary human hepatocytes and their potential in liver regeneration. We also describe recent clinical trials using hepatocytes derived from stem cells and their role in improving the phenotype of several liver diseases.

KW - Fibroblast

KW - Hepatic progenitor cells

KW - Hepatocyte transplantation

KW - Induced pluripotent stem cells

KW - Liver regeneration

KW - Mesenchymal stem/stromal cell

U2 - 10.1007/s00109-018-1638-5

DO - 10.1007/s00109-018-1638-5

M3 - Article

C2 - 29691598

VL - 96

SP - 469

EP - 481

JO - Journal of molecular medicine (Berlin, Germany)

JF - Journal of molecular medicine (Berlin, Germany)

SN - 0946-2716

IS - 6

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454